We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

PROMEGA

Promega has a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression,... read more Featured Products: More products

Download Mobile App




Genomic Sequencing Illuminates Recent Shigellosis Outbreaks

By LabMedica International staff writers
Posted on 12 Jan 2017
Shigellosis is an acute gastrointestinal infection caused by bacteria belonging to the genus Shigella. More...
Shigellosis is the third most common enteric bacterial infection in the USA with 500,000 infections, 6,000 hospitalizations, and 70 deaths each year.

There are four Shigella species that cause shigellosis: Shigella dysenteriae, considered to be the most virulent species due to its ability to produce a potent cytotoxin called Shiga toxin, while S. flexneri, S. boydii, and S. sonnei generally do not produce Shiga toxin and, therefore, cause mild forms of shigellosis.

Scientists at the California Department of Public Health (Richmond, CA, USA) and their colleagues identified 68 Shigella sonnei human isolates from California (CA); 57 outbreak-related isolates from 2014 to 2015 and 11 archival isolates from 1980 to 2008, which were serotyped by standard methods. Polymerase chain reaction (PCR) detection of the stx1 and stx2 genes and Vero cell neutralization assay for confirmation of Shiga toxin production were performed.

DNA was extracted with a Wizard Genomic DNA kit (Promega, Madison, WI, USA). Sequencing libraries were constructed using the Nextera XT (Illumina Inc, San Diego, CA, USA) library preparation kit. Sequencing was performed using 2 × 300-bp sequencing chemistry on an Illumina MiSeq sequencer. High-quality single nucleotide polymorphism (hqSNP)-based phylogeny was used to determine genetic relationships between the local California (CA) S. sonnei populations and their connection to global S. sonnei strains.

The team found two clusters in these outbreaks: one that primarily struck San Diego and the San Joaquin Valley and one more localized to the San Francisco Bay Area. The San Diego/San Joaquin strain has been in California since at least 2008. However, some of the isolates had been infected with a bacteriophage (a virus that attacks bacteria) that carried a Shiga toxin (stx) gene found in the more virulent S. flexneri and S. dysenteriae. By contrast, the strain that hit San Francisco lacked stx but contained genes that gave it resistance to the broad-spectrum fluoroquinolone class of antibiotics. The fluoroquinolone-resistance genes were similar to ones found in strains from Southeast Asia.

James P Watt, MD, MPH, the Chief of Division of Communicable Disease Control, said, “Shigella sonnei bacteria normally cause a less severe disease and are not known to produce Shiga toxin. The toxin gene was most likely acquired by Shigella sonnei via genetic exchanges with Escherichia coli and other Shigella species. Discovering a functional toxin gene was concerning in this large outbreak. Finding this gene raises concerns that illness due to Shigella sonnei could become more severe in the future.” The study was published on December 21, 2016, in the journal mSphere.

Related Links
California Department of Public Health
Promega
Illumina


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.